How Long Does Cyclosporine Stay in Your System? What the Literature Reports

What this page covers

This page summarises what the published literature reports about how long cyclosporine remains measurable in the body, how its elimination is described, what changes that timeline, and whether it appears on drug tests. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about treatment, monitoring, or medication timing. Nothing here is a protocol, and no quantity is suggested for any person.

Cyclosporine (ciclosporin, cyclosporin A) is a cyclic undecapeptide — a ring-shaped eleven-amino-acid molecule of fungal origin that works as a calcineurin inhibitor. That peptide chemistry matters for pharmacokinetics: unlike most linear therapeutic peptides, which are rapidly degraded by peptidases, cyclosporine's cyclic, heavily N-methylated structure resists enzymatic breakdown, which is why it survives oral administration and is handled largely by hepatic metabolism instead. For the broader picture of how peptide structure drives elimination speed, see how long peptides stay in your system, and for background on the molecule itself see cyclosporine.

Half-life: what the term means and what these papers reported

Half-life is the time needed for the measured concentration of a drug to fall by half once absorption and distribution are complete. It is not a property of the molecule alone; it is a property of the molecule in a particular person, measured in a particular matrix (whole blood versus plasma), with a particular assay, after a particular formulation.

An important honesty point: the verified papers used for this page are clinical-use, safety, and monitoring publications rather than dedicated single-dose pharmacokinetic studies of cyclosporine, and none of them reported a single numeric half-life value that can be quoted here. A 2024 review in Clinical Pharmacokinetics examined clinical pharmacokinetic and pharmacodynamic considerations for systemic therapies used in moderate-to-severe psoriasis, a setting in which cyclosporine is one of the long-established oral options (PMID 38280146). Because no half-life figure from the verified set can be attributed to a specific paper, this page describes the shape of cyclosporine elimination rather than inventing a number for it.

Why cyclosporine half-life values vary so widely in print

• Formulation. Older oil-based oral formulations and modern microemulsion formulations differ in how reliably they are absorbed, which changes measured exposure even when the underlying elimination rate does not.
• Matrix. Cyclosporine partitions into red blood cells and lipoproteins, so whole-blood and plasma measurements are not interchangeable; whole blood is the standard clinical matrix.
• Assay. Immunoassays that cross-react with metabolites and chromatographic methods that measure parent drug can produce different concentration curves from the same sample set.
• Population. Transplant recipients, children, and people with liver disease handle the drug differently, which is one reason monitoring is used instead of fixed assumptions.

How elimination is usually modelled

Once a drug is no longer being administered, concentration decline follows a predictable arithmetic pattern defined by its half-life. The table below is arithmetic, not a study result, and it is included only to show how clinicians and pharmacologists reason about "time to clearance" for any drug, cyclosporine included.

Pharmacology convention treats four to five half-lives as the point at which a drug is functionally eliminated and roughly the same number of half-lives as the time needed to reach steady state during repeated administration. Two separate questions follow from that: how long the drug's measurable concentration persists, and how long its biological effect persists. For an immunosuppressant those can diverge, because downstream immune effects are not strictly tied to a single blood level at a single moment.

Routes of elimination

Cyclosporine is extensively metabolised in the liver and intestinal wall by cytochrome P450 3A enzymes and is a substrate for the P-glycoprotein efflux transporter; metabolites are excreted predominantly in bile and appear in faeces, with only a small proportion of parent drug leaving in urine. These are standard pharmacology-textbook descriptions of the molecule rather than findings from the verified papers below, and they are flagged as such.

The practical consequence is that hepatic and biliary function, not kidney filtration, dominate how quickly cyclosporine leaves the body. That is somewhat counter-intuitive given that cyclosporine's best-described toxicity is renal: a 2004 report in Transplantation Proceedings addressed cyclosporine-induced renal dysfunction in clinical practice (PMID 15041342). Kidney injury caused by the drug does not mean the kidney is the main exit route for the drug.

Factors reported to change exposure and clearance

On the combination point, researchers reviewing the clinical pharmacokinetics and therapeutic drug monitoring of sirolimus described whole-blood concentration monitoring and the interaction between sirolimus and co-administered cyclosporine as central practical issues (PMID 10823378). A 2001 paper in the American Journal of Kidney Diseases examined the safety and efficacy of TOR inhibitors in paediatric renal transplant recipients, a population in which dose–exposure relationships differ from adults (PMID 11583941).

Why blood levels are monitored rather than assumed

Because absorption and metabolism vary so much between individuals, cyclosporine has historically been managed by therapeutic drug monitoring — measuring whole-blood concentrations at defined time points — instead of by assuming a uniform clearance curve. A 2004 Transplantation Proceedings contribution set out accumulated clinical experience with cyclosporine in transplantation (PMID 15041307). The same monitoring logic is described for related agents: researchers reviewed the proliferation inhibitor everolimus and its clinical development (PMID 12457444), reported clinical experience with everolimus in transplantation (PMID 15041396), and described early clinical experience with FTY720 as an alternative immunomodulatory approach (PMID 15041403).

Detectability and drug testing

This section states plainly what is and is not tested for.

• Standard workplace urine panels do not screen for cyclosporine. Those panels target a defined list of drugs of abuse and their metabolites. Cyclosporine is a prescription immunosuppressant, is not a controlled substance, and is not an analyte on those screens.
• Cyclosporine is routinely measured — but in a clinical context. Hospital and reference laboratories quantify it in whole blood using immunoassays or liquid chromatography–mass spectrometry, ordered by a clinician as therapeutic drug monitoring, not as a test of abstinence or misuse.
• Detection window is a monitoring concept here, not a forensic one. How long cyclosporine remains quantifiable after the last administration depends on the starting concentration, the assay's lower limit of quantification, and the individual's clearance — the same three variables that govern detectability for any drug.
• Metabolite cross-reactivity matters. Immunoassays that detect cyclosporine metabolites can report measurable signal for longer than methods that quantify only parent drug, which is one reason laboratory reports specify the method used.

Route of administration and systemic exposure

Changing the route changes the exposure curve. Intravenous administration bypasses absorption variability entirely; oral administration introduces gut-wall and first-pass metabolism; topical and intra-lesional delivery aim to concentrate drug locally while limiting systemic levels. A 2025 study in ACS Applied Materials & Interfaces described a multifunctional hydrogel microneedle patch developed and evaluated for atopic dermatitis (PMID 40327888). Systemic use in acute settings is also documented: a 2011 Gut review addressed the management of acute severe ulcerative colitis, including rescue medical therapy (PMID 21030524).

Cyclosporine Safety Signals: What Studies Report

Elimination questions sit alongside toxicity questions, because the organ that suffers is not always the organ that clears the drug.

• Renal dysfunction. A 2004 Transplantation Proceedings report dealt specifically with cyclosporine-induced renal dysfunction (PMID 15041342).
• Hyperuricemia. A 2005 review in Contributions to Nephrology examined hyperuricemia in kidney transplantation, a population in which calcineurin inhibitors are standard therapy (PMID 15604612).
• Combination regimens. A 2025 randomised controlled trial in BMC Medicine evaluated the safety and efficacy of sirolimus combined with cyclosporine in primary membranous nephropathy (PMID 40442735).
• Comparator agents. Interest in everolimus and FTY720 as alternatives or adjuncts was driven in part by calcineurin-inhibitor toxicity, as researchers discussed in reviews of everolimus (PMID 12457444) and in early clinical experience with FTY720 (PMID 15041403).

How this differs from research-peptide pharmacokinetics

Most linear research peptides are cleared within minutes to hours by peptidase degradation and renal filtration, which is why half-life extension strategies — fatty-acid acylation, PEGylation, cyclisation — exist at all. Cyclosporine sits at the opposite end of that spectrum: it is already cyclic and N-methylated, orally active, hepatically metabolised, and managed by blood-level monitoring. It is also an approved prescription medicine with decades of transplantation use behind it (PMID 15041307). Comparing the two categories directly is the most common source of confusion about "peptide half-life."

Key takeaways

• Cyclosporine's persistence is governed mainly by hepatic metabolism and biliary excretion, not renal filtration.
• No single half-life number is quoted on this page, because the verified papers cited here did not report one; a review of pharmacokinetic and pharmacodynamic considerations in psoriasis therapy covered the drug class context (PMID 38280146).
• Therapeutic drug monitoring exists precisely because exposure varies between individuals, as described in monitoring literature for related immunosuppressants (PMID 10823378).
• Standard drug-abuse panels do not include cyclosporine; clinician-ordered whole-blood assays do.
• Renal dysfunction and hyperuricemia were reported in the clinical literature on cyclosporine-containing regimens (PMID 15041342, PMID 15604612).

References

• Experience with cyclosporine (Transplantation Proceedings, 2004)
• Cyclosporine-induced renal dysfunction (Transplantation Proceedings, 2004)
• Experience with everolimus (Transplantation Proceedings, 2004)
• Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Moderate-to-Severe Psoriasis (Clinical Pharmacokinetics, 2024)
• A Multifunctional Hydrogel Microneedle Patch for Treatment of Atopic Dermatitis (ACS Applied Materials & Interfaces, 2025)
• Safety and efficacy of sirolimus combined with cyclosporine in primary membranous nephropathy: a randomized controlled trial (BMC Medicine, 2025)
• Review of the proliferation inhibitor everolimus (Expert Opinion on Investigational Drugs, 2002)
• Hyperuricemia in kidney transplantation (Contributions to Nephrology, 2005)
• FTY720: early clinical experience (Transplantation Proceedings, 2004)
• Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus (Clinical Therapeutics, 2000)
• Management of acute severe ulcerative colitis (Gut, 2011)
• Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients (American Journal of Kidney Diseases, 2001)